Cigna (CI) Stock
Major US health insurer with pharmacy and care services. Here's the price, business snapshot, and what's worth knowing about Cigna in August 2026.
Cigna Corporation (CI) is a large, US‑based health‑care and services company combining traditional health insurance with pharmacy and care‑management services through its Evernorth business. Its revenue mix includes employer and individual medical plans, Medicare products, and pharmacy benefit management and care solutions. Investors typically watch member trends, medical cost inflation, price negotiations with providers and drug‑pricing dynamics — all of which can move margins and earnings. Cigna’s business is sensitive to regulation, reimbursement changes and economic cycles that affect employer-sponsored coverage. With a market capitalisation of about $82.08 billion, it’s considered a major industry participant, but not immune to competition from insurers, PBMs and new entrants. This summary is general educational information, not personalised financial advice. Investors should consider their own circumstances, risk tolerance and seek regulated advice if needed; values can fall as well as rise and past performance is not a guide to future results.
Why It’s Moving
Cigna stays in focus as upbeat earnings and mixed analyst calls keep shares moving.
- Analysts remained constructive on Cigna after recent rating updates, but a Jefferies downgrade to Hold kept sentiment mixed and capped enthusiasm around the stock.
- Investors continued to focus on the company’s stronger-than-expected second-quarter results and raised 2026 outlook, which reinforced the view that earnings execution is still solid even if forward guidance has been cautious.
- News flow also highlighted capital-return and portfolio items, including a declared $1.56 dividend and ongoing share repurchase activity, which have helped support the stock despite broader pressure on managed-care names.
Cigna stays in focus as upbeat earnings and mixed analyst calls keep shares moving.
- Analysts remained constructive on Cigna after recent rating updates, but a Jefferies downgrade to Hold kept sentiment mixed and capped enthusiasm around the stock.
- Investors continued to focus on the company’s stronger-than-expected second-quarter results and raised 2026 outlook, which reinforced the view that earnings execution is still solid even if forward guidance has been cautious.
- News flow also highlighted capital-return and portfolio items, including a declared $1.56 dividend and ongoing share repurchase activity, which have helped support the stock despite broader pressure on managed-care names.
Sixth Month Growth Performance
next-earnings-question
The next earnings date for CI is expected to be October 29, 2026. This report should cover third-quarter 2026 results, based on the company’s typical quarterly reporting cadence. The date is an estimate rather than a formally confirmed announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cigna's stock, believing it could rise to $324.34 from $279.12.
Financial Health
Cigna is showing strong performance with good profits, cash flow, and solid revenue growth.
Dividend
Cigna's dividend yield of 2.12% offers a moderate return for income-focused investors. If you invested $1000 you would be paid $21.20 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Pharmacy & care growth
Evernorth’s pharmacy and care‑management services can drive revenue diversification and margin enhancement, though execution and pricing pressure matter.
US‑focused footprint
Cigna’s operations are primarily US‑centred, so domestic regulation and employer benefits trends heavily influence results; global shocks can still have indirect effects.
Regulation and margins
Policy shifts, reimbursement rates and drug pricing reforms can materially affect profitability — investors should factor regulatory risk into valuations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
